Antimicrobial resistance

Peggy Lillis Foundation To Convene National Summit In Washington, Dc With Leaders In The Fight Against Deadly Superbug

Retrieved on: 
Wednesday, March 20, 2019
Articles, Medicine, Health, Diarrhea, Epidemiology, Clostridioides difficile infection, RTT, C. Diff, Clostridioides difficile, Infection, Antimicrobial resistance

The Summit brings together 100 leaders in the fight against C. difficile infection, a superbug responsible for 30,000 American deaths annually.

Key Points: 
  • The Summit brings together 100 leaders in the fight against C. difficile infection, a superbug responsible for 30,000 American deaths annually.
  • More than 500,000 Americans still struggle with this infection every year, with more than 100,000 suffering multiple recurrences.
  • The Centers for Disease Control declared C. diff an urgent public health threat in 2013.
  • PLF is building a national movement to end C. difficile related harm and our Summit is a key convening and catalyst in that movement."

MiDOG® Launches Canine All-in-One Microbial Test for Identification of Pathogens and Antibiotic Resistance

Retrieved on: 
Tuesday, March 19, 2019
Articles, Health, Epidemiology, Veterinary physician, Antibiotic, Antimicrobial resistance, Infection

Using NGS technology, the MiDOG All-in-One Microbial Test, which integrates proprietary bioinformatic algorithms to extract more meaningful data, detects all infectious agents from the sample.

Key Points: 
  • Using NGS technology, the MiDOG All-in-One Microbial Test, which integrates proprietary bioinformatic algorithms to extract more meaningful data, detects all infectious agents from the sample.
  • In addition, it identifies antibiotic resistance which helps veterinarians diagnose and treat canine infections," said Dr. Janina A. Krumbeck, Director of MiDOG, LLC.
  • MiDOG, LLC owns the exclusive rights to the MiDOG All-in-One Microbial Test but is open to licensing and distribution prospects.
  • Their goal is to bring complete and accurate microbial identification of canine infections to help veterinarians make better treatment decisions.

SpeeDx Distribution Network Expands to the Middle East

Retrieved on: 
Monday, March 18, 2019
Health, Biotechnology, Genetics, Infectious diseases, Research, Medical Supplies, Science, Articles, Health, Pharmaceuticals policy, Antimicrobial resistance, Evolutionary biology, Veterinary medicine, Infection

View the full release here: https://www.businesswire.com/news/home/20190318005280/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20190318005280/en/
    SpeeDx ResistancePlus tests combine detection of infection with genetic markers linked to antibiotic resistance.
  • The SpeeDx ResistancePlus tests provide valuable information, combining detection of infection with genetic markers linked to antibiotic resistance empowering clinicians to make informed treatment decisions.
  • Founded in 2009, SpeeDx is an Australian-based private company with offices in London and the US, and distributors across Europe.
  • SpeeDx ResistancePlus tests enable Resistance Guided Therapy, improving patient outcomes by empowering practitioners to make informed clinical decisions.

Shield Diagnostics announces launch of Target-NG test for antibiotic susceptibility in Neisseria gonorrhoeae

Retrieved on: 
Wednesday, March 13, 2019
Health, Medical specialties, Bacteria, Infectious causes of cancer, RTT, Sexually transmitted diseases and infections, Neisseriales, Gonorrhea, Antibiotics, Antibiotic sensitivity, Antimicrobial resistance, Neisseria gonorrhoeae

SAN JOSE, Calif., March 13, 2019 /PRNewswire/ -- Shield Diagnostics, an Andreessen Horowitz-backed clinical laboratorytackling antibiotic resistance by bringing precision medicine to infectious disease, announced the launch of Target-NG, a rapid molecular test for antibiotic susceptibility in Neisseria gonorrhoeae.

Key Points: 
  • SAN JOSE, Calif., March 13, 2019 /PRNewswire/ -- Shield Diagnostics, an Andreessen Horowitz-backed clinical laboratorytackling antibiotic resistance by bringing precision medicine to infectious disease, announced the launch of Target-NG, a rapid molecular test for antibiotic susceptibility in Neisseria gonorrhoeae.
  • With 820,000 cases of Gonorrhea each year in the US, the CDC has named antibiotic resistant gonorrhea (dubbed "Super Gonorrhea") a top 3 urgent public health threat.
  • To slow the rate of antibiotic resistance, the last line of defence must only be used when strictly necessary.
  • The test isavailable from urine, rectal & pharyngeal samples, ensuring that complete care is provided for higher risk groups.

Global Markets Non-antibiotic Bacterial Therapeutics

Retrieved on: 
Wednesday, March 13, 2019
Health, Articles, Medicine, Antibiotic, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, Antibiotics, Infection, Antimicrobial resistance, Antibiotic use in livestock

What are the classes of non-antibiotics drugs that can treat bacterial infections alone or in conjunction with existing antibiotics?

Key Points: 
  • What are the classes of non-antibiotics drugs that can treat bacterial infections alone or in conjunction with existing antibiotics?
  • What non-antibiotic bacterial therapies are in late stage development, who are the developers, and what indications are they targeting?
  • What are the essential factors, technologies and market development issues for non-antibiotic bacterial therapeutics products?
  • What are the significant economic, technology, and regulatory factors affecting the market for non-antibiotic Bacterial Therapies
    ReportLinker is an award-winning market research solution.

Dr. Stephen Brecher Joins First Light Diagnostics Clinical Advisory Board

Retrieved on: 
Wednesday, March 13, 2019
Branches of biology, Medical specialties, Medicine, Healthcare-associated infections, Antibiotic-resistant bacteria, Gram-positive bacteria, RTT, Antimicrobial resistance, Clostridioides difficile, Medical microbiology, Infection

CHELMSFORD, Mass., March 13, 2019 /PRNewswire/ -- First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, today announced the addition of Dr. Stephen Brecher to the company's world-class, international Clinical Advisory Board.

Key Points: 
  • CHELMSFORD, Mass., March 13, 2019 /PRNewswire/ -- First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, today announced the addition of Dr. Stephen Brecher to the company's world-class, international Clinical Advisory Board.
  • "Stephen is an internationally recognized expert for his work with C. difficile infections and antibiotic resistance," said David Macdonald, CEO of First Light Diagnostics.
  • Also known as the "Chief of Staph," Dr. Brecher has been practicing clinical microbiology for 50 years.
  • "I was excited to be invited to participate as part of the First Light Diagnostics Clinical Advisory Board," said Dr. Brecher.

Global $62.06 Bn Antibiotics Market Size, Share & Trends Analysis 2019-2026 - Development of Advanced Products & Rising Collaborative Development Efforts

Retrieved on: 
Tuesday, February 26, 2019
Articles, Health, Pharmaceuticals policy, Veterinary medicine, Evolutionary biology, Antimicrobial resistance, Antibiotic, Food politics, Infection, Antibiotic use in livestock, Skin and skin structure infection

Rising prevalence of infectious diseases, especially in developing regions like Asia Pacific and Middle East, is anticipated to contribute to the market growth.

Key Points: 
  • Rising prevalence of infectious diseases, especially in developing regions like Asia Pacific and Middle East, is anticipated to contribute to the market growth.
  • Currently, the required antibiotic treatment is available only to one-third of the infected population, thereby increasing the disease burden.
  • Government reforms specific to antibiotics, such as the Generating Antibiotics Incentives Now (GAIN) Act in U.S., are projected to help boost the market growth over the forecast period.
  • Such indiscriminate use of antibiotics is anticipated to increase the risk of difficult-to-treat antibiotic-resistant infections, thereby increasing the economic burden.

Infection Control Products Come Into the Spotlight for Healthcare Facilities

Retrieved on: 
Tuesday, February 26, 2019
Health, Infectious diseases, Medicine, Epidemiology, Medical specialties, Infection control, Public health, Infection, Antibiotic, Pharmaceuticals policy, Veterinary medicine, Antimicrobial resistance

Infection control products have come into the spotlight in order to keep hospital facilities documented and maintained, as well as to protect the safety of public health.

Key Points: 
  • Infection control products have come into the spotlight in order to keep hospital facilities documented and maintained, as well as to protect the safety of public health.
  • Practitioners may use or prescribe antibiotics, anti-fungal, and anti-bacterial products or drugs in order to control infectious diseases on site.
  • However, the demand for efficient and effective infection control devices and technology is growing in an effort to potentially eliminate these incidents.
  • To achieve these goals, Infection Prevention professionals must be involved in all decisions affecting the delivery of patient care.

Infection Control Products Come Into the Spotlight for Healthcare Facilities

Retrieved on: 
Tuesday, February 26, 2019
Infectious diseases, Health, Medicine, Epidemiology, Medical specialties, Infection control, Infection, Antibiotic, Antimicrobial resistance, Vaginitis

Infection control products have come into the spotlight in order to keep hospital facilities documented and maintained, as well as to protect the safety of public health.

Key Points: 
  • Infection control products have come into the spotlight in order to keep hospital facilities documented and maintained, as well as to protect the safety of public health.
  • Practitioners may use or prescribe antibiotics, anti-fungal, and anti-bacterial products or drugs in order to control infectious diseases on site.
  • However, the demand for efficient and effective infection control devices and technology is growing in an effort to potentially eliminate these incidents.
  • To achieve these goals, Infection Prevention professionals must be involved in all decisions affecting the delivery of patient care.

The global antibiotics market size is expected to reach USD 62.06 billion by 2025 expanding at a CAGR of 4.0%

Retrieved on: 
Monday, February 25, 2019
Articles, Health, Pharmaceuticals policy, Veterinary medicine, Evolutionary biology, Antimicrobial resistance, Antibiotic, Antibiotic resistance, Antibiotic use in livestock

Rising prevalence of infectious diseases, especially in developing regions like Asia Pacific and Middle East, is anticipated to contribute to the market growth.

Key Points: 
  • Rising prevalence of infectious diseases, especially in developing regions like Asia Pacific and Middle East, is anticipated to contribute to the market growth.
  • Government reforms specific to antibiotics, such as the Generating Antibiotics Incentives Now (GAIN) Act in U.S., are projected to help boost the market growth over the forecast period.
  • Such indiscriminate use of antibiotics is anticipated to increase the risk of difficult-to-treat antibiotic-resistant infections, thereby increasing the economic burden.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.